Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis
Aims Standard doses of daptomycin at 4 and 6 mg/kg were used for the treatment of skin and soft tissue for infections and bacteraemia, respectively. However, increased doses of daptomycin are recommended for complicated infections by Gram‐positive organisms. Methods A systematic review was conducted...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2023-04, Vol.89 (4), p.1291-1303 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1303 |
|---|---|
| container_issue | 4 |
| container_start_page | 1291 |
| container_title | British journal of clinical pharmacology |
| container_volume | 89 |
| creator | Samura, Masaru Takada, Keisuke Hirose, Naoki Kurata, Takenori Nagumo, Fumio Uchida, Masaki Inoue, Junki Tanikawa, Koji Enoki, Yuki Taguchi, Kazuaki Matsumoto, Kazuaki Ueda, Takashi Fujimura, Shigeru Mikamo, Hiroshige Takesue, Yoshio Mitsutake, Kotaro |
| description | Aims
Standard doses of daptomycin at 4 and 6 mg/kg were used for the treatment of skin and soft tissue for infections and bacteraemia, respectively. However, increased doses of daptomycin are recommended for complicated infections by Gram‐positive organisms.
Methods
A systematic review was conducted using 4 databases. We compared treatment success between standard‐dose (SD, 4–6 mg/kg) and high‐dose (HD, >6 mg/kg) daptomycin in patients with all‐cause bacteraemia, complicated bacteraemia, infective endocarditis, osteomyelitis and foreign body/prosthetic infection as the primary outcome. We also compared the success between SD and HD2 (≥8 mg/kg) daptomycin treatments in patients with these diseases as the secondary outcome. The incidence of creatine phosphokinase (CPK) elevation was evaluated as safety.
Results
In patients with complicated bacteraemia and infective endocarditis, the treatment success was significantly lower in the SD group than in the HD group (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.30–0.76 and OR 0.50, 95% CI 0.30–0.82) and HD2 group (OR 0.38, 95% CI 0.21–0.69 and OR 0.30, 95% CI 0.15–0.60), respectively. A significant difference was demonstrated only in the HD2 group in patients with bacteraemia, including simple infection. SD did not decrease the success rate for the treatment of osteomyelitis and foreign body/prosthetic infection. The incidence of elevated CPK was significantly lower in SD group than in HD group.
Conclusion
SD daptomycin was associated with significantly lower treatment success than HD in patients with complicated bacteraemia/infective endocarditis. The CPK elevation should be considered in patients treated with high daptomycin doses. |
| doi_str_mv | 10.1111/bcp.15671 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2769590802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2769590802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3601-39f5d89b85e3eeaefbf93f01c8be793990fceac90f9a7379c34e425ebd5db4a83</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EglJY8APIS1ikteM6idmVipdUCRawjibOmBrlRZxSsuMT-Ea-BLcFdszmzmiOzuIScsLZiPsZZ7oZcRnFfIcMuIhkEPJQ7pIBEywKZCj5ATl07oUxLngk98mBiCIlwgkbkPdZXTbQWldXtDa0WyBFY6wG3VOocurAYNevX67zN7T518fn5rOwzwu_57VDmkPT1WWvbXVBp9T1rsMSOqtpi28WVxu-xA48DxUUvbPuiOwZKBwe_-SQPF1fPc5ug_n9zd1sOg-0iBgPhDIyT1SWSBSIgCYzShjGdZJhrIRSzGgE7UNBLGKlxQQnocQsl3k2gUQMydnW27T16xJdl5bWaSwKqLBeujSMIyUVS1jo0fMtqtvauRZN2rS2hLZPOUvXRae-6HRTtGdPf7TLrMT8j_xt1gPjLbCyBfb_m9LL2cNW-Q0eSYxo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2769590802</pqid></control><display><type>article</type><title>Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Samura, Masaru ; Takada, Keisuke ; Hirose, Naoki ; Kurata, Takenori ; Nagumo, Fumio ; Uchida, Masaki ; Inoue, Junki ; Tanikawa, Koji ; Enoki, Yuki ; Taguchi, Kazuaki ; Matsumoto, Kazuaki ; Ueda, Takashi ; Fujimura, Shigeru ; Mikamo, Hiroshige ; Takesue, Yoshio ; Mitsutake, Kotaro</creator><creatorcontrib>Samura, Masaru ; Takada, Keisuke ; Hirose, Naoki ; Kurata, Takenori ; Nagumo, Fumio ; Uchida, Masaki ; Inoue, Junki ; Tanikawa, Koji ; Enoki, Yuki ; Taguchi, Kazuaki ; Matsumoto, Kazuaki ; Ueda, Takashi ; Fujimura, Shigeru ; Mikamo, Hiroshige ; Takesue, Yoshio ; Mitsutake, Kotaro</creatorcontrib><description>Aims
Standard doses of daptomycin at 4 and 6 mg/kg were used for the treatment of skin and soft tissue for infections and bacteraemia, respectively. However, increased doses of daptomycin are recommended for complicated infections by Gram‐positive organisms.
Methods
A systematic review was conducted using 4 databases. We compared treatment success between standard‐dose (SD, 4–6 mg/kg) and high‐dose (HD, >6 mg/kg) daptomycin in patients with all‐cause bacteraemia, complicated bacteraemia, infective endocarditis, osteomyelitis and foreign body/prosthetic infection as the primary outcome. We also compared the success between SD and HD2 (≥8 mg/kg) daptomycin treatments in patients with these diseases as the secondary outcome. The incidence of creatine phosphokinase (CPK) elevation was evaluated as safety.
Results
In patients with complicated bacteraemia and infective endocarditis, the treatment success was significantly lower in the SD group than in the HD group (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.30–0.76 and OR 0.50, 95% CI 0.30–0.82) and HD2 group (OR 0.38, 95% CI 0.21–0.69 and OR 0.30, 95% CI 0.15–0.60), respectively. A significant difference was demonstrated only in the HD2 group in patients with bacteraemia, including simple infection. SD did not decrease the success rate for the treatment of osteomyelitis and foreign body/prosthetic infection. The incidence of elevated CPK was significantly lower in SD group than in HD group.
Conclusion
SD daptomycin was associated with significantly lower treatment success than HD in patients with complicated bacteraemia/infective endocarditis. The CPK elevation should be considered in patients treated with high daptomycin doses.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.15671</identifier><identifier>PMID: 36693240</identifier><language>eng</language><publisher>England</publisher><subject>Anti-Bacterial Agents - adverse effects ; Bacteremia - drug therapy ; daptomycin ; Daptomycin - adverse effects ; efficacy ; Endocarditis - chemically induced ; Endocarditis - complications ; Endocarditis - drug therapy ; high dose ; Humans ; meta‐analysis ; Osteomyelitis - chemically induced ; Osteomyelitis - drug therapy ; Retrospective Studies ; safety ; standard dose ; Treatment Outcome</subject><ispartof>British journal of clinical pharmacology, 2023-04, Vol.89 (4), p.1291-1303</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3601-39f5d89b85e3eeaefbf93f01c8be793990fceac90f9a7379c34e425ebd5db4a83</citedby><cites>FETCH-LOGICAL-c3601-39f5d89b85e3eeaefbf93f01c8be793990fceac90f9a7379c34e425ebd5db4a83</cites><orcidid>0000-0002-5934-0670 ; 0000-0002-8637-1237</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.15671$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.15671$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36693240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samura, Masaru</creatorcontrib><creatorcontrib>Takada, Keisuke</creatorcontrib><creatorcontrib>Hirose, Naoki</creatorcontrib><creatorcontrib>Kurata, Takenori</creatorcontrib><creatorcontrib>Nagumo, Fumio</creatorcontrib><creatorcontrib>Uchida, Masaki</creatorcontrib><creatorcontrib>Inoue, Junki</creatorcontrib><creatorcontrib>Tanikawa, Koji</creatorcontrib><creatorcontrib>Enoki, Yuki</creatorcontrib><creatorcontrib>Taguchi, Kazuaki</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Ueda, Takashi</creatorcontrib><creatorcontrib>Fujimura, Shigeru</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><creatorcontrib>Takesue, Yoshio</creatorcontrib><creatorcontrib>Mitsutake, Kotaro</creatorcontrib><title>Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims
Standard doses of daptomycin at 4 and 6 mg/kg were used for the treatment of skin and soft tissue for infections and bacteraemia, respectively. However, increased doses of daptomycin are recommended for complicated infections by Gram‐positive organisms.
Methods
A systematic review was conducted using 4 databases. We compared treatment success between standard‐dose (SD, 4–6 mg/kg) and high‐dose (HD, >6 mg/kg) daptomycin in patients with all‐cause bacteraemia, complicated bacteraemia, infective endocarditis, osteomyelitis and foreign body/prosthetic infection as the primary outcome. We also compared the success between SD and HD2 (≥8 mg/kg) daptomycin treatments in patients with these diseases as the secondary outcome. The incidence of creatine phosphokinase (CPK) elevation was evaluated as safety.
Results
In patients with complicated bacteraemia and infective endocarditis, the treatment success was significantly lower in the SD group than in the HD group (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.30–0.76 and OR 0.50, 95% CI 0.30–0.82) and HD2 group (OR 0.38, 95% CI 0.21–0.69 and OR 0.30, 95% CI 0.15–0.60), respectively. A significant difference was demonstrated only in the HD2 group in patients with bacteraemia, including simple infection. SD did not decrease the success rate for the treatment of osteomyelitis and foreign body/prosthetic infection. The incidence of elevated CPK was significantly lower in SD group than in HD group.
Conclusion
SD daptomycin was associated with significantly lower treatment success than HD in patients with complicated bacteraemia/infective endocarditis. The CPK elevation should be considered in patients treated with high daptomycin doses.</description><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Bacteremia - drug therapy</subject><subject>daptomycin</subject><subject>Daptomycin - adverse effects</subject><subject>efficacy</subject><subject>Endocarditis - chemically induced</subject><subject>Endocarditis - complications</subject><subject>Endocarditis - drug therapy</subject><subject>high dose</subject><subject>Humans</subject><subject>meta‐analysis</subject><subject>Osteomyelitis - chemically induced</subject><subject>Osteomyelitis - drug therapy</subject><subject>Retrospective Studies</subject><subject>safety</subject><subject>standard dose</subject><subject>Treatment Outcome</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EglJY8APIS1ikteM6idmVipdUCRawjibOmBrlRZxSsuMT-Ea-BLcFdszmzmiOzuIScsLZiPsZZ7oZcRnFfIcMuIhkEPJQ7pIBEywKZCj5ATl07oUxLngk98mBiCIlwgkbkPdZXTbQWldXtDa0WyBFY6wG3VOocurAYNevX67zN7T518fn5rOwzwu_57VDmkPT1WWvbXVBp9T1rsMSOqtpi28WVxu-xA48DxUUvbPuiOwZKBwe_-SQPF1fPc5ug_n9zd1sOg-0iBgPhDIyT1SWSBSIgCYzShjGdZJhrIRSzGgE7UNBLGKlxQQnocQsl3k2gUQMydnW27T16xJdl5bWaSwKqLBeujSMIyUVS1jo0fMtqtvauRZN2rS2hLZPOUvXRae-6HRTtGdPf7TLrMT8j_xt1gPjLbCyBfb_m9LL2cNW-Q0eSYxo</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Samura, Masaru</creator><creator>Takada, Keisuke</creator><creator>Hirose, Naoki</creator><creator>Kurata, Takenori</creator><creator>Nagumo, Fumio</creator><creator>Uchida, Masaki</creator><creator>Inoue, Junki</creator><creator>Tanikawa, Koji</creator><creator>Enoki, Yuki</creator><creator>Taguchi, Kazuaki</creator><creator>Matsumoto, Kazuaki</creator><creator>Ueda, Takashi</creator><creator>Fujimura, Shigeru</creator><creator>Mikamo, Hiroshige</creator><creator>Takesue, Yoshio</creator><creator>Mitsutake, Kotaro</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5934-0670</orcidid><orcidid>https://orcid.org/0000-0002-8637-1237</orcidid></search><sort><creationdate>202304</creationdate><title>Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis</title><author>Samura, Masaru ; Takada, Keisuke ; Hirose, Naoki ; Kurata, Takenori ; Nagumo, Fumio ; Uchida, Masaki ; Inoue, Junki ; Tanikawa, Koji ; Enoki, Yuki ; Taguchi, Kazuaki ; Matsumoto, Kazuaki ; Ueda, Takashi ; Fujimura, Shigeru ; Mikamo, Hiroshige ; Takesue, Yoshio ; Mitsutake, Kotaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3601-39f5d89b85e3eeaefbf93f01c8be793990fceac90f9a7379c34e425ebd5db4a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Bacteremia - drug therapy</topic><topic>daptomycin</topic><topic>Daptomycin - adverse effects</topic><topic>efficacy</topic><topic>Endocarditis - chemically induced</topic><topic>Endocarditis - complications</topic><topic>Endocarditis - drug therapy</topic><topic>high dose</topic><topic>Humans</topic><topic>meta‐analysis</topic><topic>Osteomyelitis - chemically induced</topic><topic>Osteomyelitis - drug therapy</topic><topic>Retrospective Studies</topic><topic>safety</topic><topic>standard dose</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samura, Masaru</creatorcontrib><creatorcontrib>Takada, Keisuke</creatorcontrib><creatorcontrib>Hirose, Naoki</creatorcontrib><creatorcontrib>Kurata, Takenori</creatorcontrib><creatorcontrib>Nagumo, Fumio</creatorcontrib><creatorcontrib>Uchida, Masaki</creatorcontrib><creatorcontrib>Inoue, Junki</creatorcontrib><creatorcontrib>Tanikawa, Koji</creatorcontrib><creatorcontrib>Enoki, Yuki</creatorcontrib><creatorcontrib>Taguchi, Kazuaki</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Ueda, Takashi</creatorcontrib><creatorcontrib>Fujimura, Shigeru</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><creatorcontrib>Takesue, Yoshio</creatorcontrib><creatorcontrib>Mitsutake, Kotaro</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samura, Masaru</au><au>Takada, Keisuke</au><au>Hirose, Naoki</au><au>Kurata, Takenori</au><au>Nagumo, Fumio</au><au>Uchida, Masaki</au><au>Inoue, Junki</au><au>Tanikawa, Koji</au><au>Enoki, Yuki</au><au>Taguchi, Kazuaki</au><au>Matsumoto, Kazuaki</au><au>Ueda, Takashi</au><au>Fujimura, Shigeru</au><au>Mikamo, Hiroshige</au><au>Takesue, Yoshio</au><au>Mitsutake, Kotaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>89</volume><issue>4</issue><spage>1291</spage><epage>1303</epage><pages>1291-1303</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>Aims
Standard doses of daptomycin at 4 and 6 mg/kg were used for the treatment of skin and soft tissue for infections and bacteraemia, respectively. However, increased doses of daptomycin are recommended for complicated infections by Gram‐positive organisms.
Methods
A systematic review was conducted using 4 databases. We compared treatment success between standard‐dose (SD, 4–6 mg/kg) and high‐dose (HD, >6 mg/kg) daptomycin in patients with all‐cause bacteraemia, complicated bacteraemia, infective endocarditis, osteomyelitis and foreign body/prosthetic infection as the primary outcome. We also compared the success between SD and HD2 (≥8 mg/kg) daptomycin treatments in patients with these diseases as the secondary outcome. The incidence of creatine phosphokinase (CPK) elevation was evaluated as safety.
Results
In patients with complicated bacteraemia and infective endocarditis, the treatment success was significantly lower in the SD group than in the HD group (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.30–0.76 and OR 0.50, 95% CI 0.30–0.82) and HD2 group (OR 0.38, 95% CI 0.21–0.69 and OR 0.30, 95% CI 0.15–0.60), respectively. A significant difference was demonstrated only in the HD2 group in patients with bacteraemia, including simple infection. SD did not decrease the success rate for the treatment of osteomyelitis and foreign body/prosthetic infection. The incidence of elevated CPK was significantly lower in SD group than in HD group.
Conclusion
SD daptomycin was associated with significantly lower treatment success than HD in patients with complicated bacteraemia/infective endocarditis. The CPK elevation should be considered in patients treated with high daptomycin doses.</abstract><cop>England</cop><pmid>36693240</pmid><doi>10.1111/bcp.15671</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5934-0670</orcidid><orcidid>https://orcid.org/0000-0002-8637-1237</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2023-04, Vol.89 (4), p.1291-1303 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2769590802 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Anti-Bacterial Agents - adverse effects Bacteremia - drug therapy daptomycin Daptomycin - adverse effects efficacy Endocarditis - chemically induced Endocarditis - complications Endocarditis - drug therapy high dose Humans meta‐analysis Osteomyelitis - chemically induced Osteomyelitis - drug therapy Retrospective Studies safety standard dose Treatment Outcome |
| title | Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T04%3A01%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20efficacy%20and%20safety%20of%20standard%E2%80%90%20and%20high%E2%80%90dose%20daptomycin:%20A%20systematic%20review%20and%20meta%E2%80%90analysis&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Samura,%20Masaru&rft.date=2023-04&rft.volume=89&rft.issue=4&rft.spage=1291&rft.epage=1303&rft.pages=1291-1303&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.15671&rft_dat=%3Cproquest_cross%3E2769590802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2769590802&rft_id=info:pmid/36693240&rfr_iscdi=true |